KR100787783B1 - Cosmetic Composition for Preventing Skin Aging Comprising the Scopoletin As Active Ingredient - Google Patents

Abstract

The present invention relates to a cosmetic composition for preventing skin aging containing scopoletin as an active ingredient. The cosmetic composition of the present invention enhances the synthesis of collagen, a protein constituting the dermal matrix, and enhances the expression of integrins involved in the interaction between the matrix and the cells of the dermis, effectively improving skin wrinkles and skin elasticity and preventing skin aging. It can be usefully used.

Scopoletin, skin aging, wrinkles, cosmetics

Description

Cosmetic composition for preventing skin aging containing scopoline as an active ingredient {Cosmetic Composition for Preventing Skin Aging Comprising the Scopoletin As Active Ingredient}

The present invention relates to a cosmetic composition for preventing skin aging and a cosmetic composition for improving skin wrinkles containing scopoline as an active ingredient.

The primary function of the skin is to protect the human body from external stimuli such as temperature, humidity and ultraviolet light. However, when the skin is exposed to external stimuli such as strong ultraviolet rays, stress, and malnutrition, the skin may age, such as wrinkle formation, loss of elasticity, and keratinization. Collagen and elastic fibers (elastin) present in the dermal layer of the skin structure is the main protein that controls the elasticity of the skin. Biosynthesis of collagen fibers is affected internally and externally. Internally, aging (reduction of estrogen) causes cell activity to decrease and collagen fibers to decrease. External factors include free radicals generated by excessive irradiation of UV rays and stress, which react with the -SH group of proteins to inhibit the activity of enzymes or to degrade collagen and elastin (Matrix Metalloproteinases: MMPS). ) Increases the expression of collagenase, causing aging that reduces wrinkles and elasticity of the skin. In particular, over-irradiation of UV light may cause wrinkles, thickening of the skin, sagging of the skin, loss of elasticity, roughness of the skin, dryness of the skin, and skin stains that occur as skin tissue gradually changes with age. It is known to accelerate.

Currently, cosmetics or skin protectants containing various skin protection ingredients such as retinol, retinoid, vitamin C, flavonoids and tocopherol have been developed to suppress or slow down the progression of skin. In the final formulation, the potency is low, the efficacy is mild, and the skin irritation has a serious problem.

On the other hand, Korean Patent Application No. 1997-60849 discloses a skin anti-aging cosmetic composition containing a serine of retinol, alpha hydroxy acid, vitamins, in particular beta hydroxy acid, and Korea Patent Application No. 1998-18636 An anti-aging cosmetic composition comprising an amino polymer as an active ingredient is disclosed. In addition, Korean Patent Application No. 1994-7002880 discloses a cosmetic composition synergistically as an antioxidant containing ginkgo extract and at least one polyphenol derivative, and Korean Patent Application No. 1996-69236 discloses L-2- Disclosed is a composition for preventing skin aging comprising an oxothiazolidine-4-carboxylic acid derivative.

Throughout this specification, numerous papers and patent documents are referenced and their citations are indicated in parentheses. The disclosures of cited papers and patent documents are incorporated herein by reference in their entirety, and the level of the technical field to which the present invention belongs and the contents of the present invention are more clearly described.

Accordingly, the present inventors have studied to overcome the problems that the existing anti-aging cosmetics developed to suppress skin aging or to slow the progression rate have a lower titer in the final formulation, a less effective efficacy, and severe skin irritation. As a result, scopoletin has an excellent effect on improving skin wrinkles and skin elasticity by enhancing collagen synthesis and enhancing integrin expression of fibroblasts, and has excellent formulation stability and skin irritation of cosmetics containing it. The present invention was completed by confirming that it did not cause.

Accordingly, it is an object of the present invention to provide a cosmetic composition for improving skin wrinkles containing scopoline or scopoline derivatives as an active ingredient.

It is also an object of the present invention to provide a cosmetic composition for preventing skin aging containing scopoline or scopoline derivatives as an active ingredient.

Other objects and advantages of the present invention will become apparent from the following detailed description and claims.

According to one aspect of the present invention, the present invention provides a cosmetic composition for improving skin wrinkles containing scopoline or scopoline derivatives as an active ingredient.

Further, according to another aspect of the present invention, the present invention provides a cosmetic composition for preventing skin aging containing scopoline or scopoline derivatives as an active ingredient.

Scopoletin (Scopoletin) included as an active ingredient in the cosmetic composition of the present invention is a compound having a structure as shown in the general formula (1) is about 192, 7-hydroxy-6-methoxycoumarin (7-hydroxy -6-methoxycoumarin) is a coumarin derivative.

Scopoletin shows antiviral activity against Tobacco mosaic virus (MM Antonina et al., 17 (1976)) and is present in small amounts in the peels of oranges, lemons and citrus, but has been investigated in gamma rays, etc. When stress is applied, buckwheat transferase acts as a natural fungicide of plants to convert to scoparon, which is known to self-defense by inducing a large amount (IA dubery et. Al., 440 (1987), Republic of Korea Patent No. 346610) )

In addition, scopoletin is provided as a hepatitis B treatment agent (Korean Patent No. 346610), an inflammation treatment agent (Korean Patent No. 346334), etc., but it is intended to manufacture a cosmetic composition using the same, or skin aging, especially skin wrinkles. Has not been studied at all.

The active ingredient of the cosmetic composition of the present invention, scopoline is Noni, cedar mugwort (Injin mugwort, heat keeper, raw mugwort), azalea root, panrameun (daecheong root), self-designated, Shiho (meat leaf root), convention fragrance, Gaza It can be separated from natural sources such as (Flesh), small fennel (Siraza), malt (barley gilt) and jujube, and can also be synthesized chemically.

On the other hand, Noni ( Morinda citrifolia ) used to isolate the scopoline in a preferred embodiment of the present invention is a medicinal plant native to the Moroccan Islands of Indonesia. Since about 6000 years ago, fruits and leaves have been used for food and medicinal purposes, and roots and stems have been used for dyeing. In Indonesia, it is called Menkd, Pache, and Diva. It is effective for all kinds of diseases. It is still used as a traditional medicine.

The scopoline of the present invention has an effect of promoting the synthesis of collagen, a protein constituting the matrix of the dermis of the dermis, and has an effect of promoting the expression of integrins involved in the interaction between the matrix and the cells of the dermis. Improves skin elasticity

The skin cells refer to cells present in the skin, and are preferably fibroblasts. The protein includes a protein necessary for structure formation and function of skin cells. Preferably collagen, elastin and integrin.

In addition, it is considered in the scope of the present invention that any derivative exhibiting integrin biosynthesis enhancement and collagen biosynthesis enhancement among scopoletin derivatives obtained by addition or substitution reaction of a substituent commonly practiced in the art is included in the scope of the present invention. It is clear to those skilled in the art.

In a preferred embodiment of the present invention, the content of scopoline is 0.000001 to 15.0% by weight, more preferably 0.0001 to 10.0% by weight, and most preferably 0.001 to 5.0% by weight based on the total cosmetic composition. If the content of scopoline is less than 0.000001% by weight, no obvious anti-aging effect, especially wrinkle improvement, can be expected. If the content of scopoline is more than 15.0% by weight, the effect of increasing the content increases. There is a problem in skin irritation and product stability.

Ingredients included in the cosmetic composition of the present invention include ingredients commonly used in cosmetic compositions in addition to scopoline as an active ingredient, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, And carriers.

Cosmetic compositions of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, Crystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

The cosmetic composition of the present invention has the use of improving skin wrinkles and preventing skin aging. As used herein, the term 'anti-aging of the skin' has a meaning including comprehensively preventing and treating skin aging. The cosmetic composition of the present invention promotes the synthesis of proteins constituting the matrix of the dermis, especially collagen, and enhances the expression of integrins involved in the interaction between the matrix and the cells of the dermis, thereby improving skin wrinkles and skin elasticity. This is indicated in the following examples. Therefore, the anti-aging of the skin, which is the use of the present invention, is interpreted to include the improvement of wrinkles, the moisturizing ability, the skin protection by the antioxidant effect, and the improvement of skin elasticity.

In addition, the cosmetic composition of the present invention does not have problems such as skin irritation induced or instability of the formulation appearing in the existing anti-aging cosmetic composition.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. .

Preparation Example 1 Isolation of Scopolytin from Noni

Scopoletin used in the present invention was isolated and identified in the following manner.

200 g of Noni stock solution (purchased by Balians Korea) was immersed in 1.2 L of 70% ethyl alcohol for 5 days, filtered, and the filtrate was dried under reduced pressure to obtain 30.3 g of Noni extract concentrate.

The Noni extract concentrate was rolled into a column tube filled with silica 230-400 mesh, and 20 ml fractionated while flowing methylene chloride and methanol in a gradient of 30: 1 to 10: 1 as a developing solvent. By qualitative analysis by thin layer chromatography, the fractions up to Rf = 0.80-0.85 were concentrated and UV lamp was used as a detector. As the developing solvent, a mixture of methylene chloride and methanol in a 10: 1 ratio was used. The structure was identified using an instrument analyzer (varian 500 M 1H NMR and GC-mass) to confirm that it is scopoline. In addition, the scoporectin standard (Sigma s2500) was finally confirmed that the scopoletin under HPLC UV (354 nm, 1.0 mL / min, 20% acetonitrile) conditions.

Experimental Example 1 Protein Synthesis Promoting Effect of Noni Extract and Scopoline

Human normal fibroblasts (Korean Cell Line Bank) were seeded to 1 × 10 ⁶ cells in each well of a 48-well microplate and incubated for 24 hours at 37 ° C. in DMEM medium. Then, after discarding the medium, the medium (experimental group) and scopoline or noni extract prepared by mixing the noni extract and scopoline obtained in Preparation Example 1 in serum-free DMEM medium so that the final concentration is as shown in Table 1 below. This was replaced with serum free DMEM medium (control) and incubated further for 24 hours. After incubation, the supernatant of each well was collected and the amount of newly synthesized protein was measured using a protein analysis kit (Proteinassay kit, Bioland, USA). The results are shown in Table 1 below.

Concentration (µg / ml) Noni extract protein production (% of control) Scopolytin protein production (% of control) Control 100.0 100.0 10 119.0 110.4 50 119.2 120.4 200 130.2 134.1 500 171.7 165.1 1000 174.6 167.0

As shown in the results of Table 1, in the experimental group to which the noni extract and scopoline were added, the amount of protein produced was much higher than the amount of protein produced in the control group. Therefore, it can be seen that noni extract and scopoline promote the protein synthesis of fibroblasts.

Experimental Example 2: Collagen Synthesis Effect

Human normal fibroblasts were seeded to 1 × 10 ⁶ cells in each well of a 48-well microplate and incubated for 24 hours at 37 ° C. in DMEM medium. Subsequently, the experimental group replaced with serum-free DMEM medium and the control group replaced with serum-free DMEM medium at a final concentration of Noni extract and scopoline 10-1000 ppm were further incubated for 24 hours. After incubation, the supernatant of each well was collected and the amount of newly synthesized collagen was measured by measuring the amount of procollagen (procollagen) type I C-peptide (PICP) using a kit (Takara, Japan). PICP amount was converted to ng / ml, and the results are shown in Table 2 below.

Treatment concentration Relative amount of type I collagen (%) relative to the control Noni Extract Scopoline No treatment (control) 100.0 100.0 10 ng / ml TGF-β1 255.1 355.1 10 μg / ml 100.0 124.3 50 μg / ml 100.0 166.1 200 μg / ml 163.7 222.1 500 μg / ml 349.5 279.5 1000 μg / ml 322.1 337.1

As shown in Table 2, the amount of collagen produced in the experimental group to which scopoline was added was much higher than the amount of collagen produced in the control group. Therefore, it was found that scopoline promotes collagen synthesis of fibroblasts.

Experimental Example 3: Integrin β1 expression enhancing effect

Human normal fibroblasts were seeded to 1 × 10 ⁶ cells in each well of a 48-well microplate and incubated for 24 hours at 37 ° C. in DMEM medium. Subsequently, the serum-free DMEM medium (experimental group) and the serum-free DMEM medium (control group) containing no scopoline were prepared so that the final concentration of scopoline was 5, 10, 20, 50, and 100 ppm, respectively. Further incubation for hours. After incubation, the expression level of integrin β1 was measured according to the EIA (Enzyme immnoassay) method (MK008 kit, Takara, Japan). In detail, cells were harvested by centrifugation, cell extracts were prepared, and the cell extracts were treated in wells coated with anti-integrin β1 antibody. Secondary antibodies were added and reacted at 4 ° C. for 45 minutes and then detected by OPD (ο-Phenylenediamine-HCl). After the stained OPD was dissolved in the OPD solution, the absorbance was measured at 530 nm with an ELISA reader, and the results are shown in Table 3.

Concentration (ng / ml) OD ₅₃₀ 0 0.504 0.5 0.531 One 0.589 2 0.563 5 0.787 10 0.987

From the results in Table 3, it was found that scopoline promotes the synthesis of integrin β1, which plays an important role in cell adhesion in a concentration-dependent manner.

Preparation Example 2 Preparation of Scopolytin-Containing Cosmetics

In order to clinically test the effects of scopoline of the present invention on the improvement of protein synthesis, collagen synthesis, and integrin β1 expression on skin wrinkle improvement and skin elasticity improvement, the cosmetic composition of the cream formulation with the ingredients and contents of Table 4 below. Was prepared and this was referred to as 'prescription example'. To prepare a cosmetic formulation of the cream formulation of the same as the ingredients of Table 4 and does not contain scopoline was set as 'comparative example'.

Prescription cosmetics containing scopoline ingredient Content (% by weight) Scopoline 1.0 Lipophilic monostearate 2.0 Cetearyl Alcohol 2.2 Stearic acid 1.5 Beeswax 1.0 Polysorbate 60 1.5 Sorbitan stearate 0.6 Cured Vegetable Oil 1.0 Squalane 3.0 Mineral oil 5.0 Trioctanoine 5.0 Dimethicone 1.0 Sodium magnesium silicate 0.1 glycerin 5.0 Betaine 3.0 Triethanolamine 1.0 Sodium hyaluronate 4.0 Preservative, fragrance, coloring a very small amount Distilled water Remaining amount Sum 100

Experimental Example 4: Evaluation of the wrinkle improvement effect of the cosmetic containing scopoletin-clinical trial

Wrinkle improvement effect of the cosmetic of the present invention containing scopoline was evaluated through a practical test. The cream of the prescription example containing 1% of scopoline and the cream of the comparative example in which scopoline was replaced with purified water were used. Twenty 30-40 year old women were randomly divided into two groups, and the creams of the prescription and the comparative example were washed twice every morning, and then the appropriate amount of the cream was corrected continuously for 2 months around the eyes. Wrinkle improvement effect of each subject was evaluated through visual observation and the results are shown in Table 5 below.

Wrinkle improvement effect (visual evaluation) Test Sample Excellent wrinkle improvement Wrinkle improvement effect slightly No wrinkle improvement Effectiveness% Prescription Example 8 8 4 70.0 Comparative example One 3 16 45.0

Through the experimental results of Table 5, it can be seen that the cosmetics of the prescription example containing scopoline shows a higher wrinkle improvement effect than the comparative example. In addition, skin irritation could not be observed in the subjects who applied the prescription of the present invention to the skin.

Experimental Example 5: skin elasticity improving effect-clinical trial

In the constant temperature and humidity room of 22 ° C and relative humidity of 45%, the creams of the above-described formulations and the comparative examples were applied to the eyes of 30 healthy women (average age 33.7 years) for a certain amount (0.03 g / 16 cm 2) for 12 weeks. Then, skin elasticity of each group was measured using a skin elasticity measuring instrument (Cutometer SEM 575, C + K Electronic Co., Germany). The results are shown in Table 6 below.

Skin elasticity improvement degree (%) Prescription Example Comparative example 33.6 15.8

Through the results in Table 6, it was confirmed that the improvement of skin elasticity of the cream of the prescription example containing scopoline of the present invention is much higher than the cream of the comparative example containing no scopolein, and the skin elasticity improvement is excellent.

Experimental Example 6: skin irritation test

The skin irritation of the cosmetics containing the scopoletin of this invention was evaluated. Experiments were carried out using the cream of the formulation and the cream of the comparative example containing scopoletin.

To test the skin irritation of the cosmetics, a patch test was conducted using a Haye's Test Chamber in 20 healthy adult men and women. Wipe the test site with 70% ethanol and dry it, and place a chamber (Finn chamber, 100 × 10, EPITEST, Finland) in which 15 μg or 15 μl of the prepared test substance is added to the inside of the forearm of the test subject. It was. The patch was applied for 24 hours, the patch was removed, and the test site was marked with a marker pen. 1 hour and 24 hours after each removal (1 hour after removal, 24 hours = 24 hours, 48 hours including patch attachment) using magnifier (8MC-150, DAZOR, USA) Was observed. Skin response was determined according to the regulations of the International Contact Dermatitis Research Group (ICDRG) (Table 7), the average skin reactivity was calculated by the following equation and the results are shown in Table 8.

Evaluation criteria and score of skin reaction sign score Evaluation standard - 0 No response, normal skin ± 0.5 Faint or light erythema + 1.0 Boundary but weak erythema, edema and papules ++ 2.0 Pronounced erythema, papules and vesicles +++ 3.0 Severe erythema and vesicle formation ++++ 6.0 Cannon formation

Test substance 24 hours 48 hours Average skin reactivity (n = 20) ± + ++ ± + ++ Prescription Example One - -  One - - 0.42 Comparative example One - -  One - - 0.42

As shown in Table 8, it was found that the skin reactivity of the cream of the comparative example which does not contain the scopoline of the present invention is very low and does not cause skin irritation by other ingredients of the cream. In addition, the addition of scopolein did not show any skin irritation.

Experimental Example 7: Stability Test of the Formulation

Formulation stability experiments were carried out using the cream of the formulation containing scopoline of the present invention and the cream of the comparative example without scopoline.

Evaluation criteria for long-term preservation stability of the cosmetics in units of 1 week, 1 month and 6 months in a thermostat and room temperature of 4 ℃, 45 ℃, 50 ℃ and 4 ℃-45 ℃ cycle (Cycle) Was evaluated, and the results are shown in Table 10.

Good O Instability X detach △

Preservation conditions Prescription Example Comparative example 4 ℃ 1 week 0 0 1 month 0 0 6 months 0 0 45 ℃ 1 week 0 0 1 month 0 0 6 months 0 0 50 ℃ 1 week 0 0 1 month 0 0 6 months 0 0 Cycle 1 week 0 0 1 month 0 0 6 months 0 0 Room temperature 1 week 0 0 1 month 0 0 6 months 0 0

As shown in Table 10, when the stability of the cream of the comparative example does not contain the active ingredient scopoletin, it can be seen that there is no problem in stability by the other ingredients of the cosmetic composition, the scopoline Since long-term storage stability also appeared in the cosmetics of the prescription containing it, it turned out that there is no problem in stability by addition of the active ingredient scopoletin.

As described in detail above, the present invention provides a cosmetic composition for preventing skin aging containing scopoline as an active ingredient. The cosmetic of the present invention enhances the biosynthesis of collagen constituting the matrix of the dermis of the skin, and contains scopoletin as an active ingredient which is excellent in enhancing the expression of integrin involved in the interaction between the matrix and the cells of the dermis. It is effective in preventing skin aging due to its excellent wrinkle improvement and skin elasticity. In addition, the cosmetic of the present invention does not cause skin irritation and excellent stability of the formulation.

Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims (5)

Cosmetic composition for improving skin wrinkles containing scopoline as an active ingredient. delete The cosmetic composition according to claim 1, wherein the scopoline enhances collagen synthesis and enhances expression of integrin. The cosmetic composition according to claim 1, wherein the scopoletin is contained in an amount of 0.0001-10.0% by weight based on the total weight of the cosmetic composition. The group of claim 1 wherein the cosmetic is a group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays. Cosmetic composition, characterized in that it has a formulation selected from.